Advanced

Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.

Wallin, Åsa LU ; Andreasen, Niels; Eriksson, Sture; Båtsman, Stellan; Näsman, Birgitta; Ekdahl, Anne; Kilander, Lena; Grut, Mikaela; Rydén, Marie and Wallin, Anders, et al. (2007) In Dementia and Geriatric Cognitive Disorders 23(3). p.150-160
Abstract
Background/Aims: Clinical short-term trails have shown positive effects of donepezil treatment in patients with Alzheimer's disease. The outcome of continuous long-term treatment in the routine clinical settings remains to be investigated. Methods: The Swedish Alzheimer Treatment Study (SATS) is a descriptive, prospective, longitudinal, multicentre study. Four hundred and thirty-five outpatients with the clinical diagnosis of Alzheimer's disease, received treatment with donepezil. Patients were assessed with Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), global rating (CIBIC) and Instrumental Activities of Daily Living (IADL) at baseline and every 6 months for a total period of 3... (More)
Background/Aims: Clinical short-term trails have shown positive effects of donepezil treatment in patients with Alzheimer's disease. The outcome of continuous long-term treatment in the routine clinical settings remains to be investigated. Methods: The Swedish Alzheimer Treatment Study (SATS) is a descriptive, prospective, longitudinal, multicentre study. Four hundred and thirty-five outpatients with the clinical diagnosis of Alzheimer's disease, received treatment with donepezil. Patients were assessed with Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), global rating (CIBIC) and Instrumental Activities of Daily Living (IADL) at baseline and every 6 months for a total period of 3 years. Results: The mean MMSE change from baseline was positive for more than 6 months and in subgroups of patients for 12 months. After 3 years of treatment the mean change from baseline in MMSE-score was 3.8 points (95% CI, 3.0-4.7) and the ADAS-cog rise was 8.2 points (95% CI, 6.4-10.1). This is better than expected in untreated historical cohorts, and better than the ADAS-cog rise calculated by the Stern equation (15.6 points; 95% CI, 14.5-16.6). After 3 years with 38% of the patients remaining, 30% of the them were unchanged or improved in the global assessment. Conclusion: Three-year donepezil treatment showed a positive global and cognitive outcome in the routine clinical setting. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer's disease, Cholinesterase inhibitor, Donepezil.
in
Dementia and Geriatric Cognitive Disorders
volume
23
issue
3
pages
150 - 160
publisher
Karger
external identifiers
  • wos:000244108300003
  • scopus:33847379394
ISSN
1420-8008
DOI
10.1159/000098052
language
English
LU publication?
yes
id
7df2d824-6d5c-4886-9506-30d3f296e5e0 (old id 165526)
date added to LUP
2007-07-30 13:32:25
date last changed
2017-09-17 05:00:23
@article{7df2d824-6d5c-4886-9506-30d3f296e5e0,
  abstract     = {Background/Aims: Clinical short-term trails have shown positive effects of donepezil treatment in patients with Alzheimer's disease. The outcome of continuous long-term treatment in the routine clinical settings remains to be investigated. Methods: The Swedish Alzheimer Treatment Study (SATS) is a descriptive, prospective, longitudinal, multicentre study. Four hundred and thirty-five outpatients with the clinical diagnosis of Alzheimer's disease, received treatment with donepezil. Patients were assessed with Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), global rating (CIBIC) and Instrumental Activities of Daily Living (IADL) at baseline and every 6 months for a total period of 3 years. Results: The mean MMSE change from baseline was positive for more than 6 months and in subgroups of patients for 12 months. After 3 years of treatment the mean change from baseline in MMSE-score was 3.8 points (95% CI, 3.0-4.7) and the ADAS-cog rise was 8.2 points (95% CI, 6.4-10.1). This is better than expected in untreated historical cohorts, and better than the ADAS-cog rise calculated by the Stern equation (15.6 points; 95% CI, 14.5-16.6). After 3 years with 38% of the patients remaining, 30% of the them were unchanged or improved in the global assessment. Conclusion: Three-year donepezil treatment showed a positive global and cognitive outcome in the routine clinical setting.},
  author       = {Wallin, Åsa and Andreasen, Niels and Eriksson, Sture and Båtsman, Stellan and Näsman, Birgitta and Ekdahl, Anne and Kilander, Lena and Grut, Mikaela and Rydén, Marie and Wallin, Anders and Jonsson, Mikael and Olofsson, Hasse and Londos, Elisabet and Wattmo, Carina and Eriksdotter Jönhagen, Maria and Minthon, Lennart},
  issn         = {1420-8008},
  keyword      = {Alzheimer's disease,Cholinesterase inhibitor,Donepezil.},
  language     = {eng},
  number       = {3},
  pages        = {150--160},
  publisher    = {Karger},
  series       = {Dementia and Geriatric Cognitive Disorders},
  title        = {Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.},
  url          = {http://dx.doi.org/10.1159/000098052},
  volume       = {23},
  year         = {2007},
}